Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07201571 | A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea | completed | — | 3,131 | Samsung Medical CenterOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06333665 | PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy | completed | — | 605 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
| 1 |
| Sep 30, 2025 |
| clinicaltrials |
| NCT05271604 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 42 | BioAtla, Inc.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04417465 | First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | completed | Phase 1 | 101 | AbbVieINDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT04979000 | HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors | completed | — | 49 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07181850 | Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features(pCR-ESCC) | completed | — | 363 | Nanjing Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04180215 | A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers | completed | Phase 1 / Phase 2 | 198 | Hookipa Biotech GmbHINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | completed | Phase 1 / Phase 2 | 12 | Hoffmann-La RocheINDUSTRY | 3 | Sep 15, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06771674 | Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma | completed | — | 662 | Hookipa Biotech GmbHINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT00954226 | Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer | completed | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03552965 | Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC | completed | N/A | 23 | University of ArkansasOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05323656 | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | completed | Phase 2 | 55 | Calliditas Therapeutics Suisse SAINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT06272513 | Influencing Factors for Physical Activity in People With Head and Neck Cancer(ProAct-HNC) | completed | — | 20 | Kantonsspital Winterthur KSWOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05880082 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer(PPIO-004-EC001) | completed | Phase 2 | 118 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | completed | Early Phase 1 | 8 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03623646 | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.(CITHARE) | completed | Phase 2 | 11 | Institut Claudius RegaudOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02013154 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab(P102) | completed | Phase 1 | 151 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | completed | Phase 2 | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03797625 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | completed | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT06654999 | How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions. | completed | — | 115 | Skin Analytics LimitedINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03635164 | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | completed | Phase 1 | 21 | University of Colorado, DenverOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03357757 | Avelumab With Valproic Acid in Virus-associated Cancer(LATENT) | completed | Phase 2 | 39 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06112535 | Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery | completed | N/A | 60 | CMR Surgical LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | completed | Phase 4 | 101 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Jun 19, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | completed | Phase 2 | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07015333 | Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab | completed | — | 31 | Commonwealth Healthcare CorporationOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03914443 | A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 | 37 | National Cancer Center, JapanOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT05499065 | Real-time Margin Assessment in Head and Neck Cancer(LIGHTNING) | completed | Phase 2 | 23 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 432 | Regeneron PharmaceuticalsINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06757530 | Radiomics Model for Assessing Lymph Node Status in cN0 Patients withHNSCC | completed | — | 700 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT01101451 | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | completed | Phase 3 | 340 | GOG FoundationNETWORK | 3 | May 23, 2025 | clinicaltrials |
| NCT03953443 | Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC | completed | — | 25 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05516589 | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC(neoCHANCE-2) | completed | Phase 2 | 40 | West China HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Oct 1, 2025source: clinicaltrials